Login / Signup

Eligibility for subcutaneous implantable cardioverter-defibrillator in adults with congenital heart disease.

Christos ZormpasAnn Sophie Silber-PeestJörg EiringhausHenrike A K HillmannStephan HohmannJohanna Müller-LeisseMechthild Westhoff-BleckChristian VeltmannDavid Duncker
Published in: ESC heart failure (2021)
Patients with ACHD show satisfactory eligibility rates (83%) for S-ICD implantation utilizing the automated screening test, including patients with CHD of high complexity. S-ICD therapy should be considered with caution in ACHD patients with a QRS duration ≥148 ms and/or need for ventricular pacing.
Keyphrases
  • cardiac resynchronization therapy
  • left ventricular
  • heart failure
  • mass spectrometry
  • multiple sclerosis
  • machine learning
  • ms ms
  • deep learning
  • high throughput
  • catheter ablation
  • bone marrow